All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
At the American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, on Tuesday 4th April, a poster session titled “BITES Bispecifics and Checkpoints” took place.
One of the posters on display (3651 / 24) was titled “Preclinical examination of the effects of MT-3724, an engineered toxin body targeting CD20, in mantle cell lymphoma” by Shengjiang Huang from the University of Texas MD Anderson Cancer Center, Houston, TX, and colleagues.
MT-3724 binds CD20 and is take up by the cell where the toxin travels to the cytosol to enzymatically and permanently inactivates ribosomes preventing protein synthesis. MT-3724 may decrease cell proliferation and induce apoptosis in MCL.
The group analyzed the effects of MT-3724 by in vitro cell proliferation in 3 ibrutinib-sensitive cell lines and 5 ibrutinib-resistant cell lines (4 primary resistant and 1 acquired resistant). Levels of apoptotic cells in ibrutinib-sensitive and -resistant cell lines treated with MT-3724 was measured by Annexin V/ PI staining. In addition, an in vivo efficacy assay of MT-3724 in a MCL PDX model, derived from a patient resistant to a wide-range of drugs including ibrutinib, was conducted.
In conclusion, MT-3724 appears to be a potential therapeutic agent for combating ibrutinib resistance in MCL; combinations with this agent should be investigated to achieve higher efficacy.
References
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?